8-K: Medtronic Reports Strong Q3 FY25 Results Driven by Innovation and Market Growth

Medtronic announces a 2.5% increase in reported revenue and a 4.1% organic revenue growth for Q3 FY25, driven by strong performance in pulsed field ablation, pacing, structural heart, diabetes, and neuromodulation.

Summary

• Medtronic reported Q3 FY25 worldwide revenue of $8.292 billion, a 2.5% increase as reported and a 4.1% increase on an organic basis.
• GAAP diluted EPS was $1.01, a 2% increase, while non-GAAP diluted EPS was $1.39, a 7% increase.
• The company reiterated its full-year revenue and EPS guidance.
• The Cardiovascular Portfolio saw a 3.7% increase in reported revenue and a 5.0% organic increase.
• Cardiac Ablation Solutions revenue increased in the low-20s due to the adoption of pulsed field ablation (PFA) products.
• The Neuroscience Portfolio revenue increased 4.4% as reported and 5.2% organically.
• The Medical Surgical Portfolio revenue decreased 1.9% as reported and 0.4% organically.
• Diabetes revenue increased 8.4% as reported and 10.4% organically.
• Medtronic expects FY25 organic revenue growth in the range of 4.75% to 5%.
• The company continues to expect FY25 diluted non-GAAP EPS in the range of $5.44 to $5.50.

Sentiment

Score: 8

Explanation: The report is generally positive, highlighting strong organic growth, EPS improvements, and key product advancements. While there are some challenges in specific segments, the overall outlook is optimistic, supported by management's confidence in future performance.

Positives

• Strong organic revenue growth of 4.1% in Q3 FY25.
• Significant growth in Cardiac Ablation Solutions, driven by PFA products.
• Double-digit growth in Neuromodulation.
• Continued adoption of the MiniMed 780G system driving growth in the Diabetes segment.
• U.S. FDA approval for an additional pulsed field ablation manufacturing site in Galway.
• CMS coverage for Renal Denervation is expected to become final on or before October 11, 2025.

Negatives

• Medical Surgical Portfolio revenue decreased by 1.9% as reported and 0.4% organically.
• The Surgical & Endoscopy division was affected by ongoing stapling segment pressures and a transient change in U.S. distributor buying patterns.
• Acute Care & Monitoring performance included high-single digit declines in Nellcor blood oxygen management products due to a market decline in U.S. respiratory-related hospitalizations.

Risks

• The company faces risks related to competitive factors, difficulties and delays in product development, government regulation, geopolitical conflicts, and changing global trade policies.
• The Medical Surgical segment is experiencing pressure in the stapling segment.
• The Acute Care & Monitoring segment is facing challenges due to a decline in U.S. respiratory-related hospitalizations.

Future Outlook

Medtronic expects FY25 organic revenue growth in the range of 4.75% to 5% and diluted non-GAAP EPS in the range of $5.44 to $5.50.

Management Comments

• Geoff Martha, Medtronic chairman and chief executive officer, stated that the company is starting to see results from long-term investments in groundbreaking innovation.
• Gary Corona, Medtronic interim chief financial officer, mentioned that EPS came in above the high end of their guidance range and that they expect to accelerate both top and bottom-line growth in Q4.

Industry Context

Medtronic's focus on innovative technologies like pulsed field ablation aligns with the broader industry trend of minimally invasive procedures and advanced medical devices. The CMS coverage decision for Renal Denervation could significantly impact the hypertension treatment market, potentially benefiting Medtronic and its competitors in the long run.

Comparison to Industry Standards

• Medtronic's organic revenue growth of 4.1% is comparable to other large-cap medical device companies, such as Johnson & Johnson (JNJ) and Abbott Laboratories (ABT), which have also reported mid-single-digit organic growth in recent quarters.
• The growth in Cardiac Ablation Solutions, driven by PFA, positions Medtronic competitively against companies like Boston Scientific (BSX) and Johnson & Johnson (JNJ), which are also investing heavily in this area.
• Medtronic's diabetes segment competes with companies like Dexcom (DXCM) and Insulet (PODD), and the continued adoption of the MiniMed 780G system is crucial for maintaining market share.

Stakeholder Impact

• Shareholders can expect continued growth and profitability, with a focus on innovation and market expansion.
• Employees will benefit from the company's investment in new technologies and therapies.
• Customers will have access to advanced medical devices and solutions.
• Suppliers can anticipate continued demand for their products and services.
• Creditors can be confident in the company's financial stability and ability to meet its obligations.

Next Steps

• Medtronic plans to report its FY25 fourth quarter results on Wednesday, May 21, 2025.
• Medtronic plans to report its FY26 first, second, third, and fourth quarter results on Tuesday, August 19, 2025, November 18, 2025, February 17, 2026, and Wednesday, May 20, 2026, respectively.

Key Dates

Keywords

Medtronic, financial results, Q3 FY25, revenue, EPS, organic growth, pulsed field ablation, cardiovascular, neuroscience, diabetes, renal denervation